This is a working overview of storage stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-28 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
== Taxonomy == The death cap is named in Latin as such in the correspondence between the English physician Thomas Browne and Christopher Merrett. It was described by French botanist Sébastien Vaillant in 1727, who gave a succinct phrase name "Fungus phalloides, annulatus, sordide virescens, et patulus" (a phallus-shaped, ring-stemmed, dirty green mushroom with a large 'spreading' cap). In 1821, Elias Magnus Fries described it as Agaricus phalloides, but included all white amanitas within its description. Finally, in 1833, Johann Heinrich Friedrich Link settled on the name Amanita phalloides, after Persoon had named it Amanita viridis 30 years earlier. Although Louis Secretan's use of the name A. phalloides predates Link's, it has been rejected for nomenclatural purposes because Secretan's works did not use binomial nomenclature consistently; some taxonomists have, however, disagreed with this opinion. Amanita phalloides is the type species of Amanita section Phalloideae, a group that contains all of the deadly poisonous Amanita species thus far identified. Most notable of these are the species known as destroying angels, including A. virosa, A. bisporigera, A. ocreata, A. verna, and more than a dozen others. The term "destroying angel" has been applied to A. phalloides at times, but "death cap" is by far the most common vernacular name used in English. Other common names also listed include "stinking amanita" and "deadly amanita". A rarely appearing, all-white form was initially described A. phalloides f. alba by Max Britzelmayr, though its status has been unclear.
This competition could alter the post-transcriptional gene regulation (PTGR) of ADME-related genes, leading to indirect modulation of the expression of drug-metabolizing enzymes or transporters and causing DDIs with co-administered drugs. Short hairpin RNAs (shRNAs) may additionally compete with pre-miRNAs for the nuclear export protein Exportin-5 (XPO5) and the cytoplasmic ribonuclease Dicer, disrupting global miRNA biogenesis and posing further DDI risk. The U.S. Food and Drug Administration has issued guidance specific to oligonucleotide therapeutics, recommending assessment of QTc interval prolongation, immunogenicity, organ-impairment effects on PD endpoints, and the potential for RNAi machinery competition as part of the DDI risk framework for this drug class.
As the head group forms such compact bicycle structure, the head group area is quite small relative to the big tail region consisting of 4 acyl chains. Based on this special structure, the fluorescent mitochondrial indicator, nonyl acridine orange (NAO) was introduced in 1982, and was later found to target mitochondria by binding to CL. NAO has a very large head and small tail structure which can compensate with cardiolipin's small head and large tail structure, and arrange in a highly ordered way. Several studies were published utilizing NAO both as a quantitative mitochondrial indicator and an indicator of CL content in mitochondria. However, NAO is influenced by membrane potential and/or the spatial arrangement of CL, so it's not proper to use NAO for CL or mitochondria quantitative studies of intact respiring mitochondria. But NAO still represents a simple method of assessing CL content.
=== Transportation === On April 10, 2019, Premier Ford and Minister Yurek announced Ontario's transit plan for the Greater Toronto Area (GTA)—one of the largest metropolitan areas in Canada. The $30 billion dollar project would include the $10.9 billion Ontario Line, the $5.5 billion Scarborough subway extension, the $5.6 billion Yonge North subway extension to Richmond Hill, and the $4.7 billion Eglinton West extension. The province would provide $11.2 billion in funding and "wants to own the lines but leave the city and TTC to operate the subway system." Premier Ford said, "We are making the biggest and largest investment in new subways in Canadian history." The City of Toronto had already spent $224 million of public money on its own "planning and design of transit infrastructure in Toronto." The City raised concerns about delays considering the city manager—Chris Murray's "sweeping" April 16 transit expansion report, "which also suggests several projects may now be in limbo, including two Scarborough transit lines and Mayor John Tory's signature SmartTrack plan." In a December 13, 2018, City Council meeting, Toronto Transit Commission (TTC) CEO Rick Leary, said that he had not had any "direct negotiations or discussion" with the province on what "it would look like if the province uploaded the subway system"—bringing the "TTC's subway system under provincial ownership". While there were clear financial benefits to the city, the council voted to "reaffirm their desire to keep the entire TTC — subways and all" and requested more clarity from the province.
Specific impulses as high as 350 s (3.5 kN·s/kg) can be achieved, depending on the fuel. Peroxide used as an oxidizer gives a somewhat lower Isp than liquid oxygen but is dense, storable, and non-cryogenic and can be more easily used to drive gas turbines to give high pressures using an efficient closed cycle. It may also be used for regenerative cooling of rocket engines. Peroxide was used very successfully as an oxidizer in World War II German rocket motors (e.g., T-Stoff, containing oxyquinoline stabilizer, for both the Walter HWK 109-500 Starthilfe RATO externally podded monopropellant booster system and the Walter HWK 109-509 rocket motor series used for the Me 163B), most often used with C-Stoff in a self-igniting hypergolic combination, and for the low-cost British Black Knight and Black Arrow launchers. Presently, HTP is used on ILR-33 AMBER and Nucleus suborbital rockets. In the 1940s and 1950s, the Hellmuth Walter KG–conceived turbine used hydrogen peroxide for use in submarines while submerged; it was found to be too noisy and require too much maintenance compared to diesel-electric power systems. Some torpedoes used hydrogen peroxide as oxidizer or propellant. Operator error in the use of hydrogen peroxide torpedoes was named as possible causes for the sinking of HMS Sidon and the Russian submarine Kursk. SAAB Underwater Systems is manufacturing the Torpedo 2000. This torpedo, used by the Swedish Navy, is powered by a piston engine propelled by HTP as an oxidizer and kerosene as a fuel in a bipropellant system.
Sources: en.wikipedia.org
Brown sugars are granulated sugars, either containing residual molasses, or with the grains deliberately coated with molasses to produce a light- or dark-coloured sugar such as muscovado and turbinado. They are used in baked goods, confectionery, and toffees. Their darkness is due to the amount of molasses they contain. They may be classified based on their darkness or country of origin.
Laurus nobilis is a widespread relict of the laurel forests that originally covered much of the Mediterranean Basin when the climate of the region was more humid. With the drying of the Mediterranean during the Pliocene era, the laurel forests gradually retreated, and were replaced by the more drought-tolerant sclerophyll plant communities familiar today. Most of the last remaining laurel forests around the Mediterranean are believed to have disappeared approximately ten thousand years ago, although some remnants still persist in the mountains of southern Turkey, northern Syria, southern Spain, north-central Portugal, northern Morocco, the Canary Islands and in Madeira.
=== Economics === Copra production begins on coconut plantations. Coconut trees are generally spaced 9 m (30 ft) apart, allowing a density of 100–160 coconut trees per hectare. A standard tree bears around 50–80 nuts a year, and average earnings in Vanuatu (1999) were US$0.20 per kg (one kg equals 8 nuts)—so a farmer could earn approximately US$120 to US$320 yearly for each planted hectare. Copra has since more than doubled in price, and was quoted at US$540 per ton in the Philippines on a CIF Rotterdam basis (US$0.54 per kg) by the Financial Times on 9 November 2012. In 2017 the value of global exports of copra was $145-146 Million. The largest exporter was Papua New Guinea with 35% of the global total, followed by Indonesia (20%), Solomon Islands (13%) and Vanuatu (12%). The largest importer of copra is the Philippines, which imports $93.4 Million or 64% of the global total. A very large number of small farmers and tree owners produce copra, which is a vital part of their income.
==== In human fetuses ==== In human embryos and fetuses, ethanol is not metabolized via ADH as ADH enzymes are not yet expressed to any significant quantity in human fetal liver (the induction of ADH only starts after birth, and requires years to reach adult levels). Accordingly, the fetal liver cannot metabolize ethanol or other low molecular weight xenobiotics. In fetuses, ethanol is instead metabolized at much slower rates by different enzymes from the cytochrome P-450 superfamily (CYP), in particular by CYP2E1. The low fetal rate of ethanol clearance is responsible for the important observation that the fetal compartment retains high levels of ethanol long after ethanol has been cleared from the maternal circulation by the adult ADH activity in the maternal liver. CYP2E1 expression and activity have been detected in various human fetal tissues after the onset of organogenesis (ca 50 days of gestation). Exposure to ethanol is known to promote further induction of this enzyme in fetal and adult tissues. CYP2E1 is a major contributor to the so-called Microsomal Ethanol Oxidizing System (MEOS) and its activity in fetal tissues is thought to contribute significantly to the toxicity of maternal ethanol consumption. In presence of ethanol and oxygen, CYP2E1 is known to release superoxide radicals and induce the oxidation of polyunsaturated fatty acids to toxic aldehyde products like 4-hydroxynonenal (HNE). The concentration of alcohol in breast milk produced during lactation is closely correlated to the individual's blood alcohol content.
A feature exploited in the expansion of the genetic code is the fact that the aminoacyl tRNA synthetase often does not recognize the anticodon, but another part of the tRNA, meaning that if the anticodon were to be mutated the encoding of that amino acid would change to a new codon. In the ribosome, the information in mRNA is translated into a specific amino acid when the mRNA codon matches with the complementary anticodon of a tRNA, and the attached amino acid is added onto a growing polypeptide chain. When it is released from the ribosome, the polypeptide chain folds into a functioning protein. In order to incorporate a novel amino acid into the genetic code several changes are required. First, for successful translation of a novel amino acid, the codon to which the novel amino acid is assigned cannot already code for one of the 20 natural amino acids. Usually a nonsense codon (stop codon) or a four-base codon are used. Second, a novel pair of tRNA and aminoacyl tRNA synthetase are required, these are called the orthogonal set. The orthogonal set must not crosstalk with the endogenous tRNA and synthetase sets, while still being functionally compatible with the ribosome and other components of the translation apparatus. The active site of the synthetase is modified to accept only the novel amino acid. Most often, a library of mutant synthetases is screened for one which charges the tRNA with the desired amino acid. The synthetase is also modified to recognize only the orthogonal tRNA. The tRNA synthetase pair is often engineered in other bacteria or eukaryotic cells.
Sources: en.wikipedia.org
In early July 1990, Iraq complained about Kuwait's behavior, such as not respecting their quota, and openly threatened to take military action. On the 23rd, the CIA reported that Iraq had moved 30,000 troops to the Iraq–Kuwait border, and the US naval fleet in the Persian Gulf was placed on alert. Saddam believed an anti-Iraq conspiracy was developing – Kuwait had begun talks with Iran, and Iraq's rival Syria had arranged a visit to Egypt. On 15 July 1990, Saddam's government laid out its combined objections to the Arab League, including that policy moves were costing Iraq $1 billion a year, that Kuwait was still using the Rumaila oil field, and that loans made by the UAE and Kuwait could not be considered debts to its "Arab brothers". He threatened force against Kuwait and the UAE, saying: "The policies of some Arab rulers are American ... They are inspired by America to undermine Arab interests and security." The US sent aerial refuelling planes and combat ships to the Persian Gulf in response to these threats. Discussions in Jeddah, Saudi Arabia, mediated on the Arab League's behalf by Egyptian president Hosni Mubarak, were held on 31 July and led Mubarak to believe that a peaceful course could be established.
=== Mating === When ready to mate, cabbage loopers display by elevating their abdomen and fanning their wings. Males also fan out their abdominal hairs, open their genital claspers, and partially stick out their spermatophores. Males gradually expose more of their spermatophores as they wait for a mate. Upon interest, a potential mate examines the other's abdomen with antennae, and mating occurs if both agree. Mating on average occurs at 2am, but has been observed occurring between 12 and 4am. Mating generally occurs 3–4 days after emergence, but can occur up to 16 days afterwards. Usually, mating does not occur before the third day, as eggs are not fully developed upon emergence and require a few days to reach maturity. Multiple matings is a mating strategy where individuals have multiple mates in their lifetime. This is in contrast to monogamy, where individuals have one mate for life. Mating multiply can be advantageous to both sexes, which is why this strategy has evolved in many species, including the cabbage looper. For female cabbage loopers, rate of oviposition increases with the number of matings, and ultimately lay more eggs total. While it was once believed that multiple matings were necessary to fertilize all eggs, evidence shows that only one mating is needed to fertilize almost all eggs. Instead, it is more likely that the spermatophore provides nutrients to the female that confers reproductive benefits. This may explain why males produce female-attracting pheromones, as females may be seeking nutrient-rich spermatophores.
=== Excitation === In principle, coherent axial oscillations of ion rings could be excited by applying RF waveforms to the outer electrode as demonstrated in and references therein. However, if ion packets are injected away from the minimum of the axial potential (which corresponds to the thickest part of either electrode), this automatically initiates their axial oscillations, eliminating the need for any additional excitation. Furthermore, the absence of additional excitation allows the detection process to start as soon as the detection electronics recover from the voltage ramp needed for ion injection.
Narrated by Piers Gibbon, produced by Simon Nasht, directed by Chris Durlacher, made by Pilot Productions, with WGBH Nova and Rai 3 (Rai Tre) of Italy, and AVRO (AVROTROS since 2014) of the Netherlands 26 April Sweden, Sex and the Disappearing Doctors, about compulsory sterilisation in Sweden, after a law was passed in 1934; until 1975, the Swedish government had compulsory sterilised 60,000 citizens; the forty-year programme began as a eugenics programme to breed a Nordic race; historian Gunnar Broberg; environment minister Anna Lindh; writer Jan Myrdal; individuals who were unlikely to financially contribute to the Swedish state, not intelligent, or who had been labelled as anti-social, were most likely to be forcibly sterilised; anti-social youths were given the choice between being sterilised or prison; 90% of people sterilised were women, and many were single mothers of limited means; oral contraceptives made the sterilisation programme redundant; the State Institute for Racial Biology in Uppsala, and geneticist Ulf Pettersson; the documentary was conducted in a hard-hitting confrontational Panorama-style.
Anatomic pathology: areas included here are histopathology, cytopathology, electron microscopy, and gross pathology. Medical Laboratory or clinical pathology, which typically includes the following areas: Clinical microbiology: This encompasses several different sciences, including bacteriology, virology, parasitology, immunology, and mycology. Clinical chemistry: This area typically includes automated analysis of blood specimens, including tests related to enzymology, toxicology and endocrinology. Hematology: This area includes automated and manual analysis of blood cells. It also often includes coagulation. Blood bank involves the testing of blood specimens in order to provide blood transfusion and related services. Molecular diagnostics DNA testing may be done here, along with a subspecialty known as cytogenetics. Reproductive biology testing is available in some laboratories, including Semen analysis, Sperm bank and assisted reproductive technology. Layouts of clinical laboratories in health institutions vary greatly from one facility to another. For instance, some health facilities have a single laboratory for the microbiology section, while others have a separate lab for each specialty area. The testing in the laboratory is traditionally categorized by the clinical purpose of the test, which determines how the test should be used throughout the spectrum of diagnosis and care. There are four major categories namely screening tests, diagnostic tests, monitoring tests and follow-up tests.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.